A Linked Electronic Medical Record-Claims Analysis of the Clinical and Economic Outcomes of Patients Coded for Erosive Esophagitis in the United States.
Acid suppression
Erosive esophagitis
Gastroesophageal reflux disease
Healthcare costs
Proton pump inhibitor
Treatment patterns
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
received:
13
07
2023
accepted:
15
09
2023
medline:
30
10
2023
pubmed:
15
10
2023
entrez:
14
10
2023
Statut:
ppublish
Résumé
Erosive esophagitis (EE) is a severe form of gastroesophageal reflux disease commonly treated with proton pump inhibitors (PPIs). The aim of this retrospective, observational cohort study was to describe the characteristics and healthcare burden of patients with EE. We identified adults in the USA with an EE diagnosis between January 1, 2016 and February 28, 2019 in a linked dataset containing electronic health records (EHR) from the Veradigm Network EHR and claims data from Komodo Health. Patients were required to have 1 year of baseline data and 3 years of follow-up data. Patients were stratified by the number of PPI lines of therapy (LOT) during the 4-year study period. We descriptively captured patient characteristics and treatment patterns, along with all-cause and EE-related healthcare utilization and costs. Among the 158,347 qualifying adults with EE, 71,958 (45.4%) had 1 PPI LOT, 14,985 (9.5%) had 2 LOTs, 15,129 (9.6%) had 3+ LOTs, and 56,275 (35.5%) did not fill a PPI prescription. Omeprazole and pantoprazole comprised more than 70% of any LOT, with patients commonly switching between the two. Mean (standard deviation) annualized all-cause and EE-related healthcare costs in the follow-up period were $16,853 ($70,507) and $523 ($3659), respectively. Both all-cause and EE-related healthcare costs increased with LOTs. Patients with EE are commonly treated with prescription PPIs; however, 19.0% of patients cycled through multiple PPIs. Higher PPI use was associated with a higher comorbidity burden and higher healthcare costs compared to 0 PPI use.
Identifiants
pubmed: 37837526
doi: 10.1007/s12325-023-02688-7
pii: 10.1007/s12325-023-02688-7
pmc: PMC10611850
doi:
Substances chimiques
Proton Pump Inhibitors
0
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
5489-5501Informations de copyright
© 2023. The Author(s).
Références
El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63:871–80.
doi: 10.1136/gutjnl-2012-304269
pubmed: 23853213
Pisegna J, Holtmann G, Howden CW, et al. Review article: oesophageal complications and consequences of persistent gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2004;20(Suppl 9):47–56.
doi: 10.1111/j.1365-2036.2004.02240.x
pubmed: 15527464
pmcid: 6736593
Savarino E, de Bortoli N, De Cassan C, et al. The natural history of gastro-esophageal reflux disease: a comprehensive review. Dis Esophagus. 2017;30:1–9.
pubmed: 27862680
Ronkainen J, Talley NJ, Storskrubb T, et al. Erosive esophagitis is a risk factor for Barrett’s esophagus: a community-based endoscopic follow-up study. Am J Gastroenterol. 2011;106:1946.
doi: 10.1038/ajg.2011.326
pubmed: 21946284
Peery AF, Crockett SD, Murphy CC, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology. 2019;156:254–272.e11.
doi: 10.1053/j.gastro.2018.08.063
pubmed: 30315778
Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: a comprehensive review. Gut Liver. 2017;11:27–37.
doi: 10.5009/gnl15502
pubmed: 27840364
Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022;117:27–56.
doi: 10.14309/ajg.0000000000001538
pubmed: 34807007
pmcid: 8754510
Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology. 1996;111:85–92.
doi: 10.1053/gast.1996.v111.pm8698230
pubmed: 8698230
Delshad SD, Almario CV, Chey WD, Spiegel BMR. Prevalence of gastroesophageal reflux disease and proton pump inhibitor-refractory symptoms. Gastroenterology. 2020;158:1250–1261.e2.
doi: 10.1053/j.gastro.2019.12.014
pubmed: 31866243
Ruigómez A, Johansson S, Wernersson B, Fernández Cantero O, García Rodríguez LA. Gastroesophageal reflux disease in primary care: using changes in proton pump inhibitor therapy as an indicator of partial response. Scand J Gastroenterol. 2012;47:751–61.
doi: 10.3109/00365521.2012.679682
pubmed: 22519917
Shah S, Cappell K, Sedgley R, et al. Diagnosis and treatment patterns among patients with newly diagnosed Helicobacter pylori infection in the United States 2016–2019. Sci Rep. 2023;13:1375.
doi: 10.1038/s41598-023-28200-3
pubmed: 36697470
pmcid: 9876904
Birnbaum H, Greenberg PE, Tang J, et al. Antidepressant treatment patterns and costs among US employees. J Med Econ. 2009;12:36–45.
doi: 10.3111/13696990902757389
pubmed: 19450063
Measuring price change in the CPI: medical care. Consumer Price Index. 2022. https://www.bls.gov/cpi/factsheets/medical-care.htm . Accessed 2022 Sep 20.
Gawron AJ, Pandolfino JE, Miskevics S, Lavela SL. Proton pump inhibitor prescriptions and subsequent use in US veterans diagnosed with gastroesophageal reflux disease. J Gen Intern Med. 2013;28:930–7.
doi: 10.1007/s11606-013-2345-0
pubmed: 23400526
pmcid: 3682032
Gawron AJ, Pandolfino J, Miskevics S, LaVela SL. Initial proton pump inhibitor characteristics associated with long-term prescriptions in US veterans diagnosed with gastro-oesophageal reflux disease. J Pharm Health Serv Res. 2014;5:157–64.
doi: 10.1111/jphs.12057
Konturek PC, Brzozowski T, Konturek SJ. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. J Physiol Pharmacol. 2011;62:591–9.
pubmed: 22314561
Sharma P, Yadlapati R. Pathophysiology and treatment options for gastroesophageal reflux disease: looking beyond acid. Ann N Y Acad Sci. 2021;1486:3–14.
doi: 10.1111/nyas.14501
pubmed: 33015827
Targownik LE, Fisher DA, Saini SD. AGA clinical practice update on de-prescribing of proton pump inhibitors: expert review. Gastroenterology. 2022;162:1334–42.
doi: 10.1053/j.gastro.2021.12.247
pubmed: 35183361
Li B-Z, Threapleton DE, Wang J-Y, et al. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ. 2015;351: h4052.
doi: 10.1136/bmj.h4052
pubmed: 26290044
pmcid: 4541168
Graham DY, Tansel A. Interchangeable use of proton pump inhibitors based on relative potency. Clin Gastroenterol Hepatol. 2018;16:800–808.e7.
doi: 10.1016/j.cgh.2017.09.033
pubmed: 28964908
Ichikawa H, Sugimoto M, Sugimoto K, Andoh A, Furuta T. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis. J Gastroenterol Hepatol. 2016;31(4):716–26.
doi: 10.1111/jgh.13233
pubmed: 26580676
Sheikh I, Waghray A, Waghray N, Dong C, Wolfe MM. Consumer use of over-the-counter proton pump inhibitors in patients with gastroesophageal reflux disease. Am J Gastroenterol. 2014;109:789–94.
doi: 10.1038/ajg.2013.421
pubmed: 24896751